SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.
Location: Ireland, Dublin City, Dublin
Employees: 11-50
Total raised: $323.8M
Founded date: 2020
Investors 3
| Date | Name | Website |
| - | Forbion | forbion.co... |
| 13.05.2024 | Bioqube Ve... | bioqubeven... |
| 16.06.2022 | GIMV | gimv.com |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 30.10.2024 | - | $92M | - |
| 07.09.2024 | Series B | $75M | - |
| 30.04.2024 | Series B | $75M | Forbion |
| 11.08.2022 | Series A | $37.89M | - |
| 19.11.2020 | Series A | $43.91M | Forbion |
Mentions in press and media 20
| Date | Title | Description |
| 31.10.2024 | SynOx Therapeutics: A New Dawn in Cancer Treatment | In the world of biopharmaceuticals, every breakthrough feels like a beacon of hope. SynOx Therapeutics, a late clinical-stage company based in Dublin and Oxford, has recently raised a staggering $92 million in its Series B financing round. ... |
| 30.10.2024 | SynOx Therapeutics Raises Additional Funding in Series B Round; Total to $92M | SynOx Therapeutics, a Dublin, Ireland- and Oxford, UK-based late clinical-stage biopharmaceutical company developing a novel treatment for CSF-1 related and macrophage-driven disorders, raised additional funding in Series B round. The round... |
| 30.10.2024 | Dublin-based SynOx adds new capital to Series B, raising total to €84.8 million | SynOx, a late clinical-stage biopharmaceutical company developing a novel treatment for CSF-1 related and macrophage-driven disorders, announced that it has raised additional funding in a final close of its Series B financing. The Series B ... |
| 30.10.2024 | SynOx Therapeutics Adds New Investor and Capital to Series B Financing, Raising Total to $92 Million, and Doses First Patients in Phase 3 Trial | Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1 Receptor Targeted Antibody, for the Treatment... |
| 07.09.2024 | SynOx Therapeutics: Pioneering a New Era in Cancer Treatment | In the world of biopharmaceuticals, innovation is the lifeblood. SynOx Therapeutics, a late-stage clinical company based in Dublin and Oxford, is making waves with its promising drug, emactuzumab. This monoclonal antibody targets Tenosynovi... |
| 07.09.2024 | SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT | Dublin, Ireland and Oxford, UK, 22 April 2024: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company, is pleased to announce the close of a $75m Series B financing. The financing was co-led... |
| 07.09.2024 | SynOx Therapeutics secures up to $35m debt financing with Hercules Capital | • SynOx is developing emactuzumab – a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibody • Provides flexible loan facility to support additional clinical work and activities to drive its successful registration ... |
| 30.04.2024 | SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab | • SynOx is developing emactuzumab - a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibody • Provides flexible loan facility to support additional clinical work and activities to drive its successful registration ... |
| 30.04.2024 | SynOx Therapeutics Raises Up To $35M in Debt Financing | SynOx Therapeutics Limited, a Dublin, Ireland- and Oxford, UK-based late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases, raised up to $35M in Deb... |
| 23.04.2024 | SynOx Therapeutics: Revolutionizing TGCT Treatment with Emactuzumab | SynOx Therapeutics Limited, a clinical biopharmaceutical company, has secured a whopping $75 million in Series B financing to advance the development of Emactuzumab, a groundbreaking monoclonal antibody for the treatment of Tenosynovial Gia... |
Show more